全部

1·Does KRAS Testing in Metastatic Colorectal Cancer Impact Overall Survival?

【译】在转移性结直肠癌影响总生存期KRAS测试吗？

2·It is therefore important to identify prognostic factors for metastatic colorectal cancer patients.

因此，为转移的大肠直肠癌病患确认预后的因子是重要的。

3·Objective: to determine the therapeutic effect and toxicity of cetuximab and chemotherapy agents in metastatic colorectal cancer.

目的：探讨西妥昔单抗联合化疗治疗转移性结直肠癌的疗效和不良反应。

4·For example, the Panel used data for the monoclonal antibodies cetuximab and panitumumab, which inhibit the EGF receptor (EGFR) in metastatic colorectal cancer.

例如，委员会使用的关于单克隆抗体西妥昔单抗和帕尼单抗(它们抑制转移性结直肠癌的表皮生长因子受体egfr)的数据。

5·OBJECTIVE To evaluate the efficacy and safety of bevacizumab when added to first-line irinotecan-based chemotherapy in patients with metastatic colorectal cancer.

目的观察贝伐单抗与化疗药物联合用于晚期结直肠癌一线治疗的近期疗效和安全性。

6·Objective Analysis of synchronous metastatic liver cancer of colorectal cancer for risk factors to improve the level of early diagnosis.

目的探讨大肠癌同期肝转移的危险因素，提高早期诊断水平。

7·Results: All of 49 patients with colorectal cancer received one stage resection of primary tumors and metastatic tumors.

结果：该组49例结直肠癌患者原发癌均获切除，同时一期切除肝转移癌。

8·With colorectal cancer, only 10 percent with metastatic disease survive five years.

对于出现转移的肠癌患者仅有10%能存活五年。